Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Metabolism and nutrition disorders – page 49

  • 755 clinical trials
  • 276 recruiting
  • 239 conditions
  • 26 countries

Conditions in this area

239 conditions with trials, the busiest first

Obesity122Type 2 diabetes mellitus85Overweight58Type 1 diabetes mellitus41Endocrine ophthalmopathy26Metabolic dysfunction-associated steatohepatitis24Diabetes mellitus21Non-alcoholic steatohepatitis17Type IIa hyperlipidaemia15Glycogen storage disease type II14Hypercholesterolaemia14Diabetic neuropathy13Diabetic retinal oedema13Diabetic foot12Alpha-1 antitrypsin deficiency11Chronic kidney disease10Fabry's disease10Osteoporosis10Hypertriglyceridaemia9Hypoparathyroidism9Acromegaly8Adrenoleukodystrophy8Dyslipidaemia8Iron deficiency8+215

Clinical trials in Metabolism and nutrition disorders

755 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

755 clinical trials

Type 1 diabetes mellitus

Not recruiting

Evaluation of fenofibrate treatment on beta cell function in children and adolescents newly diagnosed with type 1 diabetes

Registered drug
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Fenofibrate Micronised
  • Sponsor:Medical University Of Warsaw

Type IIa hyperlipidaemia+1

Not recruiting

Study of Bempedoic Acid for Children Aged 6-17 with Familial Hypercholesterolemia

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years
  • Substances:Bempedoic Acid
  • Sponsor:Esperion Therapeutics Inc.

Endocrine ophthalmopathy

Not recruiting

Study of Efgartigimod PH20 SC for Adults with Thyroid Eye Disease

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Hypertriglyceridaemia

Not recruiting

Study on Plozasiran and ARO-APOC3 for Adults with Severe Hypertriglyceridemia

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Endocrine ophthalmopathy

Not recruiting

Study of Efgartigimod for Adults with Thyroid Eye Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency

Not recruiting

Study on INZ-701 for Improving Survival in Infants with ENPP1 Deficiency

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Recombinant Human Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Fused To The Fc Fragment Of Igg1
  • Sponsor:Inozyme Pharma Inc.

Familial hypertriglyceridaemia

Not recruiting

Study on the Effects of ARO-APOC3 for Adults with Familial Chylomicronemia Syndrome

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Ornithine transcarbamoylase deficiency

Not recruiting

Study of Avalotcagene Ontaparvovec for Patients Aged 12 and Older with Late-onset Ornithine Transcarbamylase Deficiency

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:Ultragenyx Pharmaceutical Inc.

Arteriosclerosis+2

Not recruiting

Long-term Safety Study of INZ-701 for Patients with ENPP1 and ABCC6 Deficiencies, Including Pseudoxanthoma Elasticum and Generalized Arterial Calcification of Infancy

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Recombinant Human Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Fused To The Fc Fragment Of Igg1
  • Sponsor:Inozyme Pharma Inc.

Hypothyroidism

Not recruiting

Study on Levothyroxine and Sildenafil for Improving Erectile Function in Patients with Subclinical Hypothyroidism and Erectile Dysfunction

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Levothyroxine
  • Sponsor:Asociacion Instituto De Investigacion Sanitaria Biobizkaia

Metachromatic leukodystrophy

Not recruiting

Study on Gene Therapy with Atidarsagene Autotemcel for Patients with Metachromatic Leukodystrophy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Atidarsagene Autotemcel
  • Sponsor:Orchard Therapeutics (Europe) Limited

Pituitary-dependent Cushing's syndrome

Not recruiting

Study of SPI-62 for Treating ACTH-Dependent Cushing's Syndrome in Patients with Cushing's Disease or Ectopic ACTH/CRH Secretion

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Clofutriben
  • Sponsor:Sparrow Pharmaceuticals Inc.

Substances studied in this area

The therapies tested most often in Metabolism and nutrition disorders trials.

Semaglutide77 clinical trialsSodium Chloride25 clinical trialsDapagliflozin23 clinical trialsTirzepatide17 clinical trialsEmpagliflozin16 clinical trialsCagrilintide15 clinical trialsPlacebo15 clinical trialsColecalciferol14 clinical trialsMetformin12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.